Johnson & Johnson (JNJ) Upgraded to "Buy" by Johnson Rice

Core Viewpoint - Johnson & Johnson has been upgraded to a "Buy" rating, reflecting strong market performance and growth potential in its various segments [1] Group 1: Market Performance - Johnson & Johnson's market capitalization has increased by $63 billion over the past three months, driven by a 17.7% rise in share price [2][6] - The stock is currently priced at $174.21, with a slight decrease of 1.12%, and has fluctuated between a low of $174.12 and a high of $176.64 today [5] Group 2: Sales Growth - Innovative Medicine sales increased by 2.4%, despite the expiration of Stelara's patent, indicating the company's resilience and innovation [2][6] - MedTech sales rose by 6.1%, supported by contributions from Abiomed, Shockwave, and new product launches, highlighting the company's expanding market presence [3][6] Group 3: Technical Analysis - The stock has shown strong technical performance, consistently trading above its 50-day and 200-day moving averages since mid-June, with a "golden cross" occurring in mid-July [4]